Roche Holding AG (Roche Holding AG) Debt-to-Equity

: 1.05 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

Roche Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5,424 Mil. Roche Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $30,170 Mil. Roche Holding AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $33,898 Mil. Roche Holding AG's debt to equity for the quarter that ended in Dec. 2023 was 1.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Roche Holding AG's Debt-to-Equity or its related term are showing as below:

RHHBY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.42 Med: 0.94 Max: 1.33
Current: 1.05

During the past 13 years, the highest Debt-to-Equity Ratio of Roche Holding AG was 1.33. The lowest was 0.42. And the median was 0.94.

RHHBY's Debt-to-Equity is ranked worse than
86.55% of 855 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs RHHBY: 1.05

Roche Holding AG Debt-to-Equity Historical Data

The historical data trend for Roche Holding AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.48

0.42

1.33

0.95

1.05

Roche Holding AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity																1.33	1.10	0.95	0.96	1.05

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Debt-to-Equity falls into.

Roche Holding AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Roche Holding AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5424.376	+	30169.981)	/	33898.011
	=	1.05

Roche Holding AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5424.376	+	30169.981)	/	33898.011
	=	1.05

Roche Holding AG (OTCPK:RHHBY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Roche Holding AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG (Roche Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.